Products
Tioguanine is commercially available in tablet form (Lanvis). It has been approved in many countries since 1973.
Structure and properties
Tioguanine (C5H5N5S, Mr = 167.2 g/mol) is a 6-thiol analog of guanine.
Effects
Tioguanine (ATC L01BB03) has cytotoxic properties as a purine antimetabolite.
Indications
For the treatment of acute myeloid leukemia. Other indications include acute lymphoblastic leukemia and chronic myeloid leukemia.
Dosage
According to the SmPC. The tablets must be taken fasting.
Contraindications
Tioguanine is contraindicated in case of hypersensitivity. For complete precautions, see the drug label.
Interactions
Drug-drug interactions have been described with aminosalicylates.
Adverse effects
The most common possible adverse effects include leukopenia,thrombocytopenia, oral mucositis, nausea, vomiting, and liver toxicity.
